Global Ibrexafungerp Citrate Tablets Market Strategic Research Report

Scope of the Report

The global Ibrexafungerp Citrate Tablets market size is predicted to grow from US$ 293 million in 2025 to US$ 989 million in 2032; it is expected to grow at a CAGR of 11.7% from 2026 to 2032.

Ibrexafungerp Citrate is a novel triterpenoid antifungal agent that exerts fungicidal effects by inhibiting the synthesis of β‑1,3‑glucan in fungal cell walls. It demonstrates potent activity against a variety of pathogenic fungi including Candida species. Administered as an oral tablet in its citrate salt form, it is mainly indicated for the treatment of vulvovaginal candidiasis and can also be used for the prophylaxis and management of invasive fungal infections. With favorable oral absorption, broad antifungal spectrum and good safety profile, it represents a valuable new option for clinical antifungal therapy.

In 2025, global ibrexafungerp citrate production reached approximately 2.1–2.3 million bottles

As the first-in-class oral triterpenoid antifungal drug worldwide, ibrexafungerp citrate holds an important innovative position in the global antifungal market due to its unique mechanism of action, broad-spectrum antifungal activity and favorable safety profile. It is mainly indicated for the treatment and prevention of vulvovaginal candidiasis and recurrent infections, while expanding its indications to areas such as invasive fungal infections. Its market growth is driven by rising global incidence of fungal diseases, increasing drug-resistant strains and limitations of existing therapies. With its differentiated advantages, it complements traditional azoles and echinocandins, showing growth potential in both gynecological anti-infective and systemic antifungal segments. Global commercialization is carried out through collaboration between innovator companies and regional partners. The approval and launch in emerging markets including China has further unlocked incremental space. Despite challenges such as pricing, insurance coverage and market education, the market continues to expand steadily with patent protection, expanded indications and improved clinical recognition, supporting continuous enhancement of long-term market value and competitiveness.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Ibrexafungerp Citrate Tablets market?

What factors are driving Ibrexafungerp Citrate Tablets market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Ibrexafungerp Citrate Tablets market opportunities vary by end market size?

How does Ibrexafungerp Citrate Tablets break out by Type, by Application?

This report presents a comprehensive overview of the global Ibrexafungerp Citrate Tablets market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Tablets
• For Oral Suspension

Segment by Combination Therapy

• Combination With Azole Antifungals
• Combination With Echinocandins

Segment by Sales Channels

• Hospitals
• Retail
• Online

Segment by Application

• Vulvovaginal Candidiasis
• Recurrent Vulvovaginal Candidiasis
• Invasive Fungal Infections
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Ibrexafungerp Citrate Tablets market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Vulvovaginal Candidiasis, Recurrent Vulvovaginal Candidiasis, Invasive Fungal Infections evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact